OBJECTIVE: To describe differences in phenotype and outcomes in North American Native (NAN) patients with rheumatoid arthritis (RA) followed prospectively and compared to white patients with RA. METHODS: Patients from a single academic center were followed over 20 years using a custom database. Data included diagnoses, year of disease onset, ethnicity, modified Health Assessment Questionnaire (mHAQ) score, patient and physician global scores, tender and swollen joint counts, treatment, serology, and erythrocyte sedimentation rate (ESR). Records of all white (n = 1315) and NAN (n = 481) patients with RA were abstracted. Cumulative treatment data and clinical measures were compared. RESULTS: Disease duration was longer in white patients compared to NAN patients (16 +/- 11 vs 14 +/- 10 years, respectively; p = 0.03). Onset age was 34 years for NAN patients and 43 years for white patients (p < 0.001). NAN patients were more frequently positive for rheumatoid factor (89% vs 74%; p < 0.001) and antinuclear antibody (57% vs 21%; p < 0.001). Although mean tender joint counts and swollen joint counts were similar, NAN patients had higher Lansbury scores (weighted joint count; 66.5 vs 49.7; p < 0.001), mHAQ scores (1.1 vs 0.9; p = 0.001), and ESR (31 vs 25 mm/h; p < 0.012). NAN patients had more frequent knee (53% vs 34%; p < 0.001) and elbow (62% vs 48%; p = 0.007) involvement. Compared to white patients, NAN patients took a higher lifetime number of disease-modifying antirheumatic drugs (3.2 +/- 1.9 vs 2.2 +/- 1.7; p < 0.001), had more combination therapy (38% vs 29%; p = 0.002), and had more frequent prednisone use (55% vs 39%; p < 0.001). CONCLUSION: Compared to white patients, NAN patients with RA develop disease earlier, are more frequently seropositive, have greater large joint involvement, and greater disease burden, although treatment is more aggressive. These differences are present early and persist throughout the disease course.
OBJECTIVE: To describe differences in phenotype and outcomes in North American Native (NAN) patients with rheumatoid arthritis (RA) followed prospectively and compared to white patients with RA. METHODS:Patients from a single academic center were followed over 20 years using a custom database. Data included diagnoses, year of disease onset, ethnicity, modified Health Assessment Questionnaire (mHAQ) score, patient and physician global scores, tender and swollen joint counts, treatment, serology, and erythrocyte sedimentation rate (ESR). Records of all white (n = 1315) and NAN (n = 481) patients with RA were abstracted. Cumulative treatment data and clinical measures were compared. RESULTS: Disease duration was longer in white patients compared to NAN patients (16 +/- 11 vs 14 +/- 10 years, respectively; p = 0.03). Onset age was 34 years for NAN patients and 43 years for white patients (p < 0.001). NAN patients were more frequently positive for rheumatoid factor (89% vs 74%; p < 0.001) and antinuclear antibody (57% vs 21%; p < 0.001). Although mean tender joint counts and swollen joint counts were similar, NAN patients had higher Lansbury scores (weighted joint count; 66.5 vs 49.7; p < 0.001), mHAQ scores (1.1 vs 0.9; p = 0.001), and ESR (31 vs 25 mm/h; p < 0.012). NAN patients had more frequent knee (53% vs 34%; p < 0.001) and elbow (62% vs 48%; p = 0.007) involvement. Compared to white patients, NAN patients took a higher lifetime number of disease-modifying antirheumatic drugs (3.2 +/- 1.9 vs 2.2 +/- 1.7; p < 0.001), had more combination therapy (38% vs 29%; p = 0.002), and had more frequent prednisone use (55% vs 39%; p < 0.001). CONCLUSION: Compared to white patients, NAN patients with RA develop disease earlier, are more frequently seropositive, have greater large joint involvement, and greater disease burden, although treatment is more aggressive. These differences are present early and persist throughout the disease course.
Authors: Jasmine R Gaddy; Evan S Vista; Julie M Robertson; Amy B Dedeke; Virginia C Roberts; Wendy S Klein; Jeremy H Levin; Fabio H Mota; Tina M Cooper; Gloria A Grim; Sohail Khan; Judith A James Journal: J Rheumatol Date: 2012-08-15 Impact factor: 4.666
Authors: Cheryl Barnabe; Bonnie Healy; Andrew Portolesi; Gilaad G Kaplan; Brenda Hemmelgarn; Charles Weaselhead Journal: BMC Health Serv Res Date: 2016-08-24 Impact factor: 2.655
Authors: Sasanka Chukkapalli; Mercedes Rivera-Kweh; Prashasnika Gehlot; Irina Velsko; Indraneel Bhattacharyya; S John Calise; Minoru Satoh; Edward K L Chan; Joseph Holoshitz; Lakshmyya Kesavalu Journal: Arthritis Res Ther Date: 2016-07-12 Impact factor: 5.156
Authors: Sytske Anne Bergstra; Arvind Chopra; Manjit Saluja; David Vega-Morales; Nimmisha Govind; Tom W J Huizinga; Annette van der Helm-van Mil Journal: RMD Open Date: 2017-12-10
Authors: Wilfreda E Thurston; Stephanie Coupal; C Allyson Jones; Lynden F J Crowshoe; Deborah A Marshall; Joanne Homik; Cheryl Barnabe Journal: Int J Equity Health Date: 2014-06-11